Dr. Peter D. Beitsch

• 
  www.baybio.org/wt/page/news/126913 - [Cached Version]
  Published on: 6/24/2008    Last Visited: 6/27/2008  

  Peter Beitsch of the Dallas Breast Center and Timothy Nichols of the Northpoint Cancer Center in Dallas, Texas.
  ...
  For many women, post lumpectomy radiation therapy can now be completed in one week with brachytherapy compared to the 6-7 weeks required for external beam therapy," said Peter Beitsch, MD, co-Principal Investigator of EXIBT and the surgeon for the first patient on the registry.Dr. Beitsch is director of the Dallas Breast Center and a Board Member of the American Society of Breast Surgeons."With the innovative Electronic Brachytherapy System, physicians now have the ability to move breast brachytherapy out of the radiation bunker, offering women more comfortable, more accessible treatment with one of their caregivers actually present in the treatment room.Electronic brachytherapy allows for a much less anxiety-producing environment for patients who already have so much on their minds.
  
  "The fact that three physician organizations involved in the treatment of breast cancer, ASBrS, ABS, and ACRO, have agreed to jointly provide oversight for the Electronic Brachytherapy patient registry speaks to the multi- disciplinary nature of breast brachytherapy treatment decisions and the potential impact this new method of delivering non-radioactive, non- isotope- based radiation treatment may have on patients," added Dr. Beitsch.

• 
  www.dallassurgicalgroup.com/doctors/index.asp - [Cached Version]
  Published on: 9/20/2007    Last Visited: 9/20/2007  

  Peter D. Beitsch, M.D., FACS >>

• 
  www.baybio.org/wt/page/news/136970 - [Cached Version]
  Published on: 9/22/2008    Last Visited: 9/26/2008  

  Presented by Peter Beitsch, MD, director, Dallas Breast Center, Dallas, TX and David Wazer, MD, professor and chairman, Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA and the Department of Radiation Oncology, Warren Alpert Medical School of Brown University, Providence, RI.

• 
  www.markkosinsmd.com/PatientPortal/Public/NewsDetails.a - [Cached Version]
  Published on: 9/22/2008    Last Visited: 10/1/2008  

  In a second study, also expected to be presented Monday at the ASTRO conference, Dr. Peter Beitsch, a surgical oncologist at Medical City Dallas Hospital, Dallas, said that radiation "seed" implants work well as an alternative to standard whole breast radiation.He used a type of accelerated partial breast irradiation (APBI) that involves a radiation seed implant, called balloon brachytherapy.
  
  After the tumor is surgically removed, the doctor inserts a small balloon into the cavity, attaches a catheter to the balloon, and delivers a high radiation dose by way of tiny radioactive seeds.
  
  Beitsch used the Mammosite Radiation Therapy System, approved by the FDA in 2002.The manufacturer, which funded the study, wanted to conduct a post-approval study, he said.
  
  Beitsch reported on 400 women (of more than 1,400 total) now followed up for almost four years.He found that the rate of early complications, such as pockets of accumulated fluid, were similar to those of patients receiving standard therapy.Cosmetic results were similar, too.
  
  The researchers reported 28 breast tumor recurrences (about 2 percent)."The range of recurrences for whole breast radiation is nearly zero to 5 percent," Beitsch said, so these results are comparable.
  
  The best candidates for the seed therapy, he said, are women age 45 years or older, with tumors of three centimeters or less and a diagnosis of ductal cancer or ductal cancer in situ (DCIS).About 40 percent of women diagnosed with breast cancer would probably be candidates, Beitsch estimated.
  ...
  "I disagree with his [Beitsch's] blanket assessments that recurrence is not a concern," he said.

• 
  biz.yahoo.com/bw/080911/20080910006592.html?.v=1 - [Cached Version]
  Published on: 9/11/2008    Last Visited: 9/11/2008  

  The ClearPath-HDR device was implanted by Dr. Peter Beitsch of the Dallas Surgical Group and treatment was successfully completed in August.
  
  "The new improved ClearPath-HDR is simple to insert and optimizes patient comfort while maintaining the advantages of tailored treatment planning with multiple catheters," said Dr. Beitsch.

• 
  www.valleyviewregional.com/healthnews/healthday/080922H - [Cached Version]
  Published on: 10/8/2008    Last Visited: 9/26/2008  

  In a second study, also expected to be presented Monday at the ASTRO conference, Dr. Peter Beitsch, a surgical oncologist at Medical City Dallas Hospital, Dallas, said that radiation "seed" implants work well as an alternative to standard whole breast radiation.He used a type of accelerated partial breast irradiation (APBI) that involves a radiation seed implant, called balloon brachytherapy.
  
  After the tumor is surgically removed, the doctor inserts a small balloon into the cavity, attaches a catheter to the balloon, and delivers a high radiation dose by way of tiny radioactive seeds.
  
  Beitsch used the Mammosite Radiation Therapy System, approved by the FDA in 2002.The manufacturer, which funded the study, wanted to conduct a post-approval study, he said.
  
  Beitsch reported on 400 women (of more than 1,400 total) now followed up for almost four years.He found that the rate of early complications, such as pockets of accumulated fluid, were similar to those of patients receiving standard therapy.Cosmetic results were similar, too.
  
  The researchers reported 28 breast tumor recurrences (about 2 percent)."The range of recurrences for whole breast radiation is nearly zero to 5 percent," Beitsch said, so these results are comparable.
  
  The best candidates for the seed therapy, he said, are women age 45 years or older, with tumors of three centimeters or less and a diagnosis of ductal cancer or ductal cancer in situ (DCIS).About 40 percent of women diagnosed with breast cancer would probably be candidates, Beitsch estimated.
  ...
  "I disagree with his [Beitsch's] blanket assessments that recurrence is not a concern," he said.
  ...
  SOURCES: Albert Blumberg, M.D., vice chairman, radiation oncology, Greater Baltimore Medical Center, Md., and chairman, American College of Radiology Commission on Radiation Oncology; Peter Beitsch, M.D, surgical oncologist, Medical City Dallas Hospital, Dallas; Timothy Whelan, B.M., BcH., professor of oncology, McMaster University, Hamilton, Ontario, Canada; 50th annual meeting, American Society for Therapeutic Radiology and Oncology, Sept. 21-25, 2008, Boston

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/w - [Cached Version]
  Published on: 6/24/2008    Last Visited: 6/24/2008  

  Peter
  ...
  weeks required for external beam therapy," said Peter Beitsch, MD, co-Principal Investigator of EXIBT and the surgeon for the first patient on the registry.Dr. Beitsch is director of the Dallas Breast Center and a Board Member of the American Society of Breast Surgeons."With the

• 
  www.breastsurgeons.org/leadership.shtml - [Cached Version]
  Published on: 9/4/2007    Last Visited: 9/4/2007  

  Peter D. Beitsch, MD
  ...
  Peter D. Beitsch, MD
  ...
  Peter D. Beitsch, MD

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 9/22/2008    Last Visited: 10/5/2008  

  Presented by Peter Beitsch, MD, director, Dallas Breast Center, Dallas, TX and David Wazer, MD, professor and chairman, Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA and the Department of Radiation Oncology, Warren Alpert Medical School of Brown University, Providence, RI.

• 
  www.rt-image.com/In_the_News/content=8404J05E48B69A8640 - [Cached Version]
  Published on: 9/2/2008    Last Visited: 9/2/2008  

  The first patient was successfully enrolled and treated in the registry by Peter Beitsch, MD, of the Dallas Breast Center and Timothy Nichols, MD, of the Northpoint Cancer Center in Dallas.

Page:  1 2 3 4